$5M settlement over "improper" OxyContin marketing
The Attorney General of the US state of Pennsylvania has announced a $5.1 million settlement with drugmaker Purdue Frederick over alleged improper marketing of the prescription painkiller OxyContin (oxycondone HCl). The deal forms part of a $160.0 million multi-state civil suit and a previously-announced criminal compensation settlement, following an investigation by several state and federal agencies, including the Food and Drug Administration's Office of Criminal Investigations (Marketletter May 21).
Tom Corbett, the Pennsylvania AG, said that nearly $2.5 million would be paid to the state's medical assistance program, with the balance going to the federal government.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze